Income from continuing
operations 856,167 114,739 7,394 978,300
as a % of revenues 13.5% 15.4%
Diluted earnings per
share
Income from continuing
operations $ 3.36 $ 0.45 $ 0.03 $ 3.84
(1) Represents the acquired in-process research and development charges of
$114,739 and $7,394 related to the TriPath and Plasso acquisitions,
respectively.
2006
As Insurance GeneOhm
Reported Settlement IPR&D Excluding
(1) (2) Items
Selling and
administrative $ 1,448,166 $ 17,000 $ - $ 1,465,166
as a % of revenues 25.2% 25.5%
Operating Income 1,141,414 (17,000) 53,300 1,177,714
as a % of revenues 19.9% 20.5%
Income taxes 310,792 (6,460) - 304,332
effective tax rate 27.6% 26.2%
Income from continuing
operations 815,110 (10,540) 53,300 857,870
as a % of revenues 14.2% 15.0%
Diluted earnings per
share
Income from continuing
operations (3) $ 3.18 $ (0.04) $ 0.21 $ 3.34
(1) Represents the effect in 2006 related to proceeds received from
insurance settlements in connection with the Company's previously owned
latex glove business.
(2) Represents the acquired in-process research and development charge of
$53,300 related to the GeneOhm acquisition.
(3) Total per share amounts may not add due to rounding.
| SOURCE BD (Becton Dickinson and Company) Copyright©2007 PR Newswire. All rights reserved |